Objective: To perform comprehensive pharmacoeconomical assessment of use etravirine and raltegravir in HIV-infected patients. Methodology: Cost-eifectiveness and budget impact analyses of etravirine or raltegravir on the top of optimized background therapy in adult treatment-experienced HIV-infected patients were conducted. Results: Cost to achieve an undetectable viral load (<50 copies/ml) were 2 958 646 rubles for etravirine-based treatment regimen and 3 859 041 rubles for raltegravir-based therapy per one HIV-infected patient treated within two years. Use of etravirine instead of raltegravir associated with budget savings in the amount of 513 225 rubles per one HIV-infected patient treated during two years. Conclusions: Etravirine shown to outperform raltegravir in terms of cost-effectiveness and budget savings in management of adult treatment-experienced HIV-infected patients.